Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
/in International Publications, Malignant Pleural Mesothelioma, Newcastle Disease Virus /von 2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900[Progress in using Newcastle disease virus for tumor therapy: a review]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
/in Hyperthermia, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2010-08-01 / Surgery 2010 Aug;148(2):325-34Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer
/in Gastric Cancer, International Publications, Newcastle Disease Virus /von 2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-96New perspectives in cancer virotherapy: bringing the immune system into play
/in International Publications, Newcastle Disease Virus /von 2010-03-01 / Immunotherapy 2010 Mar;2(2):185-99The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting
/in International Publications, Newcastle Disease Virus /von 2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-99
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de